Menü
You have to log in or sign up before you can proceed.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?: https://g.foolcdn.com/editorial/images/735995/scientists-high-five-smile.jpg
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?: https://g.foolcdn.com/editorial/images/735995/scientists-high-five-smile.jpg
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?: https://g.foolcdn.com/editorial/images/735995/scientists-high-five-smile.jpg
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

Why Shares of Omeros Dropped on Monday: https://g.foolcdn.com/editorial/images/736062/guardant.jpg
Why Shares of Omeros Dropped on Monday

Shares of Omeros (NASDAQ: OMER) were down 12.9% early Monday afternoon after the clinical-stage biopharmaceutical company released a presentation it made regarding a therapy to treat a rare blood

Could Medtronic Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/735729/healthcare-professionals-talking-to-each-other.jpg
Could Medtronic Stock Help You Become a Millionaire?

The stock market has the potential to make just about anybody with enough patience and discipline a millionaire. This is because it has historically delivered 10% annual total returns over the long

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street: https://g.foolcdn.com/editorial/images/735853/individual-investor-stock-chart-at-home-getty.jpg
This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street

These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most

Better Long-Term Buy: AbbVie or Novo Nordisk?: https://g.foolcdn.com/editorial/images/735590/pharmacist-healthcare-worker-medicine-prescription-drug.jpg
Better Long-Term Buy: AbbVie or Novo Nordisk?

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions.

Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and

3 No-Brainer Stocks to Buy in June: https://g.foolcdn.com/editorial/images/735695/scientists-looking-at-brain-scans.jpg
3 No-Brainer Stocks to Buy in June

Sell in May and go away? The old adage hasn't proven to be great advice in 2023. The stock market has risen so far in June and could go even higher.

Three Motley Fool contributors think some stocks

Why Shares of AngioDynamics Rose Friday: https://g.foolcdn.com/assets/images/fool/tmf-logo_400x400.png
Why Shares of AngioDynamics Rose Friday

Shares of AngioDynamics (NASDAQ: ANGO) were up more than 8% Friday afternoon after rising as much as 9.1% on the news the medical technology company had sold some of its assets for $100 million. The

2 Top Biotech Stocks to Buy in June: https://g.foolcdn.com/editorial/images/735368/healthcare-lab-treatment-research-scientist-1.jpg
2 Top Biotech Stocks to Buy in June

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

2 Top Biotech Stocks to Buy in June: https://g.foolcdn.com/editorial/images/735368/healthcare-lab-treatment-research-scientist-1.jpg
2 Top Biotech Stocks to Buy in June

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

2 Top Biotech Stocks to Buy in June: https://g.foolcdn.com/editorial/images/735368/healthcare-lab-treatment-research-scientist-1.jpg
2 Top Biotech Stocks to Buy in June

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

1 Stock Down 83% That Could Triple, According to Wall Street: https://g.foolcdn.com/editorial/images/735371/doctor-vaccinating-a-patient.jpg
1 Stock Down 83% That Could Triple, According to Wall Street

Biotech company Novavax (NASDAQ: NVAX) has fallen from grace over the past year, with the vaccine maker's shares dropping by 84% over the trailing-12-month period. But Wall Street hasn't given up on

Why MicroVision Stock Is Skyrocketing Again This Week: https://g.foolcdn.com/editorial/images/735787/a-person-holding-a-paper-cutout-of-a-rocket.jpg
Why MicroVision Stock Is Skyrocketing Again This Week

Shares of MicroVision (NASDAQ: MVIS) are soaring again this week. Heading into today's trading session, the machine-vision specialist's share price had risen 46.6% from last Friday's market close

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is AbbVie or Amgen the Better Bargain Buy Right Now?: https://g.foolcdn.com/editorial/images/735634/cost-vs-value.jpg
Is AbbVie or Amgen the Better Bargain Buy Right Now?

When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task

Is AbbVie or Amgen the Better Bargain Buy Right Now?: https://g.foolcdn.com/editorial/images/735634/cost-vs-value.jpg
Is AbbVie or Amgen the Better Bargain Buy Right Now?

When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task

Is AbbVie or Amgen the Better Bargain Buy Right Now?: https://g.foolcdn.com/editorial/images/735634/cost-vs-value.jpg
Is AbbVie or Amgen the Better Bargain Buy Right Now?

When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task

Can This Gene-Editing Stock Deliver 10X Returns?: https://g.foolcdn.com/editorial/images/735588/growth-chart.jpg
Can This Gene-Editing Stock Deliver 10X Returns?

Not many stocks are truly capable of generating a 1,000% return on investment within a reasonable time frame. Even so, a fair number of next-generation technology stocks have hit this lofty

This Red-Hot Growth Stock Has Soared 885% in Just 12 Months: https://g.foolcdn.com/editorial/images/735029/surprised-and-excited-person-looking-at-a-laptop.jpg
This Red-Hot Growth Stock Has Soared 885% in Just 12 Months

Buying a soaring growth stock can be both exciting and risky territory for investors. In the biotech world, all it often takes is news of an approval from the Food and Drug Administration (FDA) or

These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys

You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons

These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys

You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons

Billionaire Ken Griffin Says Artificial Intelligence (AI) Supporters Are "Making a Terrible Mistake": https://g.foolcdn.com/editorial/images/735567/ai-artificial-intelligence-robots-working-office.jpg
Billionaire Ken Griffin Says Artificial Intelligence (AI) Supporters Are "Making a Terrible Mistake"

Artificial intelligence (AI) has taken center stage in recent times. Some see it as the next technology to transform the world.

We've already gotten a taste of some of its power. Amazon uses AI to